The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 119.50
Bid: 117.50
Ask: 120.00
Change: 0.00 (0.00%)
Spread: 2.50 (2.128%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 119.50
LIT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final closure of US$150 million fund

24 Mar 2020 07:00

RNS Number : 3418H
Litigation Capital Management Ltd
24 March 2020
 

24 March 2020

 

 

Litigation Capital Management Limited

(LCM or the Company)

 

 

LCM completes final closure of US$150 million fund

 

 

Litigation Capital Management Limited (AIM:LIT), a leading international provider of disputes financing solutions, is pleased to announce the final closure of the LCM Global Alternative Returns Fund (the Fund). On 10 March 2020, LCM announced to the market a first closure of its third-party Fund at US$140 million.

 

The final US$10 million has now been subscribed by the asset management division of the large global investment bank which comprised one of the original cornerstone investors in the first closure. The subscription of that final US$10 million commitment brings the Fund to a close at US$150 million.

 

As previously announced, the Fund will be seeded with nine single case investments which include international arbitrations, class actions, commercial litigation and investor state treaty claims.

 

Patrick Moloney, CEO of LCM, commented: "The fact LCM has been able to close its first third party fund so soon after the initial announcement and in a market which is experiencing significant volatility is testament to its disciplined investment approach and the growing number of opportunities available to it."

 

"It demonstrates that sophisticated investors are seeking to invest in uncorrelated asset classes and in businesses which enjoy counter-cyclical characteristics."

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

Alma PR

Tel: 020 3405 0205

Rebecca Sanders-Hewett

LCM@almapr.co.uk

Justine James

David Ison

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is fund and/or asset management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Corporate portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGLGDXLUDDGGS
Date   Source Headline
29th Nov 20237:00 amRNSTransaction in Own Shares
28th Nov 20237:00 amRNSTransaction in Own Shares
23rd Nov 20234:51 pmRNSDirector/PDMR Shareholding
31st Oct 20233:53 pmRNSExercise of Awards
17th Oct 20231:00 pmRNSResult of AGM
10th Oct 20237:00 amRNSTransaction in Own Shares
9th Oct 20237:00 amRNSTransaction in Own Shares
5th Oct 20231:40 pmRNSDirector/PDMR Shareholding
5th Oct 20237:00 amRNSShare Buyback Programme
2nd Oct 20237:00 amRNSDividend currency entitlement
19th Sep 20237:00 amRNSFinal Results
13th Sep 20231:00 pmRNSLondon Investor Event
12th Sep 20234:17 pmRNSNotice of AGM - Correction
12th Sep 20237:00 amRNSNotice of AGM
4th Sep 20237:00 amRNSSettlement in Australian class action
30th Aug 20237:00 amRNSNotice of Results
27th Jul 20237:00 amRNSUpdate following Supreme Court ruling
20th Jul 20237:00 amRNSProgress on Fund I investment
18th Jul 20237:00 amRNSFair Value Accounting and Dividend Payment
22nd Jun 20237:00 amRNSSuccessful resolution of balance sheet investment
19th Jun 20237:00 amRNSResolution of Investment
15th May 20239:48 amRNSSettlement in Australian class action
3rd Apr 20237:00 amRNSResolution of investment
20th Mar 20237:00 amRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSHalf-year Report
9th Mar 20237:00 amRNSSettlement in Australian class action
27th Feb 20239:30 amRNSNotice of Results
23rd Feb 20237:00 amRNSProgress on direct balance sheet investment
20th Feb 20237:00 amRNSSuccessful settlement in the Carillion claim
20th Dec 20227:00 amRNSProgress on portfolio of Investments
29th Nov 20227:00 amRNSDirector/PDMR Shareholding
16th Nov 20227:04 amRNSResult of AGM
20th Oct 20227:00 amRNSNew Litigation Finance Agreement
19th Oct 20229:26 amRNSNotice of AGM
13th Oct 20223:44 pmRNSIncentive Awards
4th Oct 20227:00 amRNSSecond close of Global Alternative Returns Fund II
29th Sep 20229:30 amRNSDirector/PDMR Shareholding
26th Sep 20226:00 pmRNSDirector/PDMR Shareholding
20th Sep 20227:00 amRNSFinal Results
23rd Aug 20227:00 amRNSNotice of Results
15th Jul 20228:22 amRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSMarket Update
16th May 20227:00 amRNSLitigation Finance Agreement
4th May 202210:15 amRNSDirector/PDMR Shareholding
25th Apr 20229:30 amRNSDirector/PDMR Shareholding
11th Apr 202211:10 amRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSInterim Results
14th Mar 202210:30 amRNSHolding(s) in Company
15th Feb 20227:00 amRNSNotice of Results
14th Feb 20227:00 amRNSMary Gangemi Appointed to the Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.